Specifically, this study showed that multiple cancer cells (e.g., lymphoma, adenocarcinoma, breast and prostate cancer) maintain activated STAT3 persistently via SIP-S1PR1 signaling, without IL6-GP130 signaling26. This evidence concerns the gene IL6 and prostate cancer.